Specialists in infectious disease are protesting a gigantic overnight increase in the price of a 62-year-old drug that is the standard of care for treating a life-threatening parasitic infection. The drug, called Daraprim, was acquired in August by Turing Pharmaceuticals, a start-up run by a former hedge fund manager. Turing immediately raised the price to $750 a tablet from $13.50, bringing the annual cost of treatment for some patients to hundreds of thousands of dollars.
Google (NSDQ:GOOG) announced today a corporate restructuring that places it under the new parent company Alphabet. The company highlighted the separation of its med-device developer Life Sciences business and human-longevity focused Calico division. The new […]
In 2006, a 21-year old Andy Sandness unsuccessfully attempted suicide. He had aimed a bullet at his chin, which ended up destroying the lower half of his face. He was rushed to Mayo Clinic in […]
As people get older, their health care goals may shift from living as long as possible to maintaining a good quality of life: quality over quantity. In many cases, the medical treatment older people receive […]